Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

被引：0
|
作者：
Leitner, H.
机构：
来源：
JOURNAL FUR KARDIOLOGIE | 2016年 / 23卷 / 1-2期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：54 / 54
页数：1
相关论文
共 50 条
  • [21] Diabetes Medications and Cardiovascular Outcomes in Type 2 Diabetes
    Chi, Cecilia
    Snaith, Jennifer
    Gunton, Jenny E.
    HEART LUNG AND CIRCULATION, 2017, 26 (11): : 1133 - 1141
  • [22] Cardiovascular and mortality events in type 2 diabetes cardiovascular outcomes trials: a systematic review with trend analysis
    Lorenzo M. Vetrone
    Francesco Zaccardi
    David R. Webb
    Sam Seidu
    Nitin N. Gholap
    Dario Pitocco
    Melanie J. Davies
    Kamlesh Khunti
    Acta Diabetologica, 2019, 56 : 331 - 339
  • [23] Cardiovascular and mortality events in type 2 diabetes cardiovascular outcomes trials: a systematic review with trend analysis
    Vetrone, Lorenzo M.
    Zaccardi, Francesco
    Webb, David R.
    Seidu, Sam
    Gholap, Nitin N.
    Pitocco, Dario
    Davies, Melanie J.
    Khunti, Kamlesh
    ACTA DIABETOLOGICA, 2019, 56 (03) : 331 - 339
  • [24] Prognostic importance of cardiovascular autonomic neuropathy on cardiovascular and mortality outcomes in individuals with type 2 diabetes: The Rio de Janeiro type 2 diabetes cohort
    Cardoso, Claudia R. L.
    de Oliveira, Vinicius A. G.
    Leite, Nathalie C.
    Salles, Gil F.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2023, 196
  • [25] Empagliflozin Reduces the Risk of Mortality, Macro- and Microvascular Events in Patients with Type 2 Diabetes and Established Cardiovascular Disease
    Seufert, Jochen
    Galle, Jan-Christoph
    Manning, Martina
    Schmid, Volkmar
    Lehrke, Michael
    DIABETOLOGIE UND STOFFWECHSEL, 2017, 12 (04) : 294 - 306
  • [26] Cardiovascular outcomes in type 1 and type 2 diabetes
    Rosengren, Annika
    Dikaiou, Pigi
    DIABETOLOGIA, 2023, 66 (03) : 425 - 437
  • [27] Cardiovascular outcomes in type 1 and type 2 diabetes
    Annika Rosengren
    Pigi Dikaiou
    Diabetologia, 2023, 66 : 425 - 437
  • [28] Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease - Results From EMPA-REG OUTCOME®
    Kaku, Kohei
    Lee, Jisoo
    Mattheus, Michaela
    Kaspers, Stefan
    George, Jyothis
    Woerle, Hans-Juergen
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    Lienart, F.
    Mortelmans, J.
    Strivay, M.
    Vereecken, G.
    Keymeulen, B.
    Lamkanfi, F.
    CIRCULATION JOURNAL, 2017, 81 (02) : 227 - +
  • [29] Design of the empagliflozin cardiovascular outcome event trial in type 2 diabetes mellitus
    Inzucchi, S. E.
    Zinman, B.
    Lachin, J. M.
    Wanner, C.
    Ferrari, R.
    Bluhmki, E.
    Hantel, S.
    Johansen, O.
    Woerle, H. -J.
    Broedl, U. C.
    DIABETOLOGIA, 2013, 56 : S378 - S378
  • [30] Is the Mortality Benefit With Empagliflozin in Type 2 Diabetes Mellitus Too Good To Be True?
    Kaul, Sanjay
    CIRCULATION, 2016, 134 (02) : 94 - +
12345